Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| eras-007, encorafenib, cetuximab, palbociclib | MAPK8 | Direct | 1 | ||||||||
| tamoxifen, etoposide | MAPK8 | Direct | 1 | ||||||||
| 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis | PDPK1 | SSL via PDPK1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | AKT1 | SSL via AKT1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CSK | SSL via CSK | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | MAPK1 | SSL via MAPK1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | MAPK3 | SSL via MAPK3 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | STAT5B | SSL via STAT5B | 3 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | CSK | SSL via CSK | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | STAT5B | SSL via STAT5B | 2 | ||||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | PDPK1 | SSL via PDPK1 | 2 | ||||||||
| cpt- 11, cisplatin, celecoxib, radiation, surgery | PDPK1 | SSL via PDPK1 | 2 | ||||||||
| pazopanib | SH2B3 | SSL via SH2B3 | 2 | ||||||||
| 7-hydroxystaurosporine, fluorouracil | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CSK | SSL via CSK | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | STAT5B | SSL via STAT5B | 1 | ||||||||
| arsenic trioxide | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| arsenic trioxide | MAPK3 | SSL via MAPK3 | 1 | ||||||||
| arsenic trioxide, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide, radiation therapy | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| arsenic trioxide, radiation therapy | MAPK3 | SSL via MAPK3 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | MAPK3 | SSL via MAPK3 | 1 | ||||||||
| bevacizumab, dasatinib, placebo | CSK | SSL via CSK | 1 | ||||||||
| bevacizumab, dasatinib, placebo | STAT5B | SSL via STAT5B | 1 | ||||||||
| biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan | ATR | SSL via ATR | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, ulixertinib | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, ulixertinib | MAPK3 | SSL via MAPK3 | 1 | ||||||||
| botensilimab, balstilimab, chloroquine phosphate, celecoxib | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| capivasertib | AKT1 | SSL via AKT1 | 1 | ||||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | TP53 | SSL via TP53 | 1 | ||||||||
| celecoxib, cyclophosphamide, etoposide, thalidomide | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| celecoxib, isotretinoin, temozolomide, thalidomide | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| celecoxib, temozolomide, thalidomide, adjuvant therapy | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| ceralasertib, olaparib, durvalumab | ATR | SSL via ATR | 1 | ||||||||
| cisplatin, carboplatin, etoposide, durvalumab, ceralasertib | ATR | SSL via ATR | 1 | ||||||||
| cytoreductive surgery, perifosine, temsirolimus | AKT1 | SSL via AKT1 | 1 | ||||||||
| cytoreductive surgery, perifosine, temsirolimus | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | STAT5B | SSL via STAT5B | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | STAT5B | SSL via STAT5B | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | STAT5B | SSL via STAT5B | 1 | ||||||||
| dasatinib, mfolfox6 | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, mfolfox6 | STAT5B | SSL via STAT5B | 1 | ||||||||
| dasatinib, pharmacological study | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, pharmacological study | STAT5B | SSL via STAT5B | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | STAT5B | SSL via STAT5B | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, lomustine | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| eras-007, encorafenib, cetuximab, palbociclib | MAPK9 | SSL via MAPK9 | 1 | ||||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | AKT1 | SSL via AKT1 | 1 | ||||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | AKT1 | SSL via AKT1 | 1 | ||||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| minocycline, placebo, questionnaires | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| pazopanib, 5-fu, oxaliplatin, leukovorin (flo) | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pazopanib, lapatinib | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pazopanib, placebo | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| perifosine | AKT1 | SSL via AKT1 | 1 | ||||||||
| perifosine | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin | MAPK1 | SSL via MAPK1 | 1 | ||||||||
| temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| topotecan hydrochloride, 7-hydroxystaurosporine | PDPK1 | SSL via PDPK1 | 1 | ||||||||
| topotecan, pazopanib | SH2B3 | SSL via SH2B3 | 1 | ||||||||
| clofarabine | POLD1 | SSL via POLD1 | yes | 0 | |||||||
| gemcitabine | POLD1 | SSL via POLD1 | yes | 0 | |||||||
| gemcitabine hydrochloride | POLD1 | SSL via POLD1 | yes | 0 |